PMID: 20622315Jul 14, 2010Paper

Long-term progression pattern of chronic allograft dysfunction among kidney transplant recipients

Iranian Journal of Kidney Diseases
Hamid Reza KhalkhaliAli Ghafari

Abstract

There is little data about the pattern of disease progression in kidney transplant recipients with chronic allograft dysfunction (CAD). Extrapolating the current classification of chronic kidney disease for CAD, we studied the pattern of progression of CAD in 5 stages among our kidney transplant recipients. We performed a retrospective cohort study on 214 kidney transplant recipients with CAD. The selection criteria were a functioning kidney allograft for at least 1 year after transplantation and a progressive decline in allograft function. An event history analysis in survival data was carried out based on the stages of CAD at baseline and the end of the study. At the beginning of the study, 54.7% of the patients had CAD stage 1; 37.9%, stage 2, and 7.5%, stage 3. At the end of study, 10.3% were in stage 2; 39.7%, stage 3; 23.4%, stage 4; and 26.6%, stage 5. Patients with CAD stage 5 were 17.1% of those in stage 1, 32.1% of those in stage 2, and 67.7% of those in stage 3 at baseline. There was a significant correlation between stage of CAD at the beginning of the study and the stage of CAD at the end (r = 0.465, P < .001). Because the decline in kidney allograft function was relatively faster in advanced stages of CAD, strateg...Continue Reading

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
Kjell Tullus
Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
Rukshana Shroff, Sarah Ledermann
© 2021 Meta ULC. All rights reserved